Research programme: HD protein targeted anti-sense oligonucleotides - nLife

Drug Profile

Research programme: HD protein targeted anti-sense oligonucleotides - nLife

Alternative Names: Htt oligonucleotide - nLife

Latest Information Update: 22 Jan 2015

Price : $50

At a glance

  • Originator nLife Therapeutics
  • Class Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Antisense RNA modulators; HD protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Huntington's disease

Most Recent Events

  • 01 Sep 2014 Early research in Huntington's disease in Spain (Intranasal)
  • 01 Sep 2014 Early research in Huntington's disease in Spain (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top